Disturbance of cellular glucose transport by two prevalently used fluoroquinolone antibiotics ciprofloxacin and levofloxacin involves glucose transporter type 1

Toxicology Letters

Volumn 184, Issue 2, 2009, Pages 81-84

  Ge, Daniel Tianfang ^a   Law, Pui Ying Peggy ^a   Kong, Siu Kai ^a   Ho, Yuan Yuan ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Ciprofloxacin; Dysglycemia; Fluoroquinolone; Glucose transport; GLUT1; Levofloxacin

Indexed keywords

CELL SURFACE PROTEIN; CIPROFLOXACIN; GLUCOSE; GLUCOSE TRANSPORTER 1; LEVOFLOXACIN; MESSENGER RNA;

ARTICLE; CELL STRAIN HEPG2; CENTRAL NERVOUS SYSTEM; DRUG EFFECT; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANTI-BACTERIAL AGENTS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; CIPROFLOXACIN; GLUCOSE; GLUCOSE TRANSPORTER TYPE 1; HUMANS; OFLOXACIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 58149299653     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2008.10.017     Document Type: Article

References (32)

1. Aloj L., Caraco C., Jagoda E., Eckelman W.C., and Neumann R.D. Glut-1 and hexokinase expression: relationship with 2-fluoro-2-deoxy-d-glucose uptake in A431 and T47D cells in culture. Cancer Res. 59 (1999) 4709-4714
2. Ball P. Safety of the new fluoroquinolones compared with ciprofloxacin. J. Chemother. 12 Suppl. 1 (2000) 8-11
3. Ball P., and Tillotson G. Tolerability of fluoroquinolone antibiotics. Past, present and future. Drug Saf. 13 (1995) 343-358
4. Christ W. Central nervous system toxicity of quinolones: human and animal findings. J. Antimicrob. Chemother. 26 Suppl. B (1990) 219-225
5. Coblio N.A., Mowrey K., McCright P., Means H., and McCormick M.T. Use of a data warehouse to examine the effect of fluoroquinolones on glucose metabolism. Am. J. Health Syst. Pharm. 61 (2004) 2545-2548
6. Duelli R., and Kuschinsky W. Brain glucose transporters: relationship to local energy demand. News Physiol. Sci. 16 (2001) 71-76
7. FDA. Generic ciprofloxacin injection. FDA Consum. 40 (2006) 3
8. FDA, 2006b. Information for Healthcare Professionals. Gatifloxacin (marketed as Tequin). http://www.fda.gov/cder/drug/InfoSheets/HCP/gatifloxacinHCP.htm (accessed March 22, 2007).
9. Fujii T., Ho Y.Y., Wang D., De Vivo D.C., Miyajima T., Wong H.Y., Tsang P.T., Shirasaka Y., Kudo T., and Ito M. Three Japanese patients with glucose transporter type 1 deficiency syndrome. Brain Dev. 29 (2007) 92-97
10. Ge T.F., Law P.Y., Wong H.Y., and Ho Y.Y. Gatifloxacin affects GLUT1 gene expression and disturbs glucose homeostasis in vitro. Eur. J. Pharmacol. 573 (2007) 70-74
11. Graumlich J.F., Habis S., Avelino R.R., Salverson S.M., Gaddamanugu M., Jamma K., and Aldag J.C. Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study. Pharmacotherapy 25 (2005) 1296-1302
12. Ho Y.Y., Yang H., Klepper J., Fischbarg J., Wang D., and De Vivo D.C. Glucose transporter type 1 deficiency syndrome (Glut1DS): methylxanthines potentiate GLUT1 haploinsufficiency in vitro. Pediatr. Res. 50 (2001) 254-260
13. Horibe Y., Hosoya K., Kim K.J., and Lee V.H. Carrier-mediated transport of monocarboxylate drugs in the pigmented rabbit conjunctiva. Invest. Ophthalmol. Vis. Sci. 39 (1998) 1436-1443
14. Ishiwata Y., Sanada Y., and Yasuhara M. Effects of gatifloxacin on serum glucose concentration in normal and diabetic rats. Biol. Pharm. Bull. 29 (2006) 527-531
15. Lin G., Hays D.P., and Spillane L. Refractory hypoglycemia from ciprofloxacin and glyburide interaction. J. Toxicol. Clin. Toxicol. 42 (2004) 295-297
16. Linder J.A., Huang E.S., Steinman M.A., Gonzales R., and Stafford R.S. Fluoroquinolone prescribing in the United States: 1995 to 2002. Am. J. Med. 118 (2005) 259-268
17. Manel N., Kim F.J., Kinet S., Taylor N., Sitbon M., and Battini J.L. The ubiquitous glucose transporter GLUT-1 is a receptor for HTLV. Cell 115 (2003) 449-459
18. Marshall B.A., Ren J.M., Johnson D.W., Gibbs E.M., Lillquist J.S., Soeller W.C., Holloszy J.O., and Mueckler M. Germline manipulation of glucose homeostasis via alteration of glucose transporter levels in skeletal muscle. J. Biol. Chem. 268 (1993) 18442-18445
19. McGowan K.M., Long S.D., and Pekala P.H. Glucose transporter gene expression: regulation of transcription and mRNA stability. Pharmacol. Ther. 66 (1995) 465-505
20. Mehlhorn A.J., and Brown D.A. Safety concerns with fluoroquinolones. Ann. Pharmacother. 41 (2007) 1859-1866
21. Montel-Hagen A., Kinet S., Manel N., Mongellaz C., Prohaska R., Battini J.L., Delaunay J., Sitbon M., and Taylor N. Erythrocyte Glut1 triggers dehydroascorbic acid uptake in mammals unable to synthesize vitamin C. Cell 132 (2008) 1039-1048
22. Park-Wyllie L.Y., Juurlink D.N., Kopp A., Shah B.R., Stukel T.A., Stumpo C., Dresser L., Low D.E., and Mamdani M.M. Outpatient gatifloxacin therapy and dysglycemia in older adults. N. Engl. J. Med. 354 (2006) 1352-1361
23. Pashko S., Simons W.R., Sena M.M., and Stoddard M.L. Rate of exposure to theophylline-drug interactions. Clin. Ther. 16 (1994) 1068-1077
24. Roberge R.J., Kaplan R., Frank R., and Fore C. Glyburide-ciprofloxacin interaction with resistant hypoglycemia. Ann. Emerg. Med. 36 (2000) 160-163
25. Stahlmann R., and Lode H. Toxicity of quinolones. Drugs 58 Suppl. 2 (1999) 37-42
26. Tal M., Schneider D.L., Thorens B., and Lodish H.F. Restricted expression of the erythroid/brain glucose transporter isoform to perivenous hepatocytes in rats. Modulation by glucose. J. Clin. Invest. 86 (1990) 986-992
27. Turnidge J. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs 58 Suppl. 2 (1999) 29-36
28. Van Bambeke F., Michot J.M., Van Eldere J., and Tulkens P.M. Quinolones in 2005: an update. Clin. Microbiol. Infect. 11 (2005) 256-280
29. Wong H.Y., Chu T.S., Chan Y.W., Fok T.F., Fung L.W., Fung K.P., and Ho Y.Y. The effects of phenytoin and its metabolite 5-(4-hydroxyphenyl)-5-phenylhydantoin on cellular glucose transport. Life Sci. 76 (2005) 1859-1872
30. Wong H.Y., Chu T.S., Lai J.C., Fung K.P., Fok T.F., Fujii T., and Ho Y.Y. Sodium valproate inhibits glucose transport and exacerbates Glut1-deficiency in vitro. J. Cell. Biochem. 96 (2005) 775-785
31. Yamada C., Nagashima K., Takahashi A., Ueno H., Kawasaki Y., Yamada Y., Seino Y., and Inagaki N. Gatifloxacin acutely stimulates insulin secretion and chronically suppresses insulin biosynthesis. Eur. J. Pharmacol. 553 (2006) 67-72
32. Zhanel G.G., Ennis K., Vercaigne L., Walkty A., Gin A.S., Embil J., Smith H., and Hoban D.J. A critical review of the fluoroquinolones: focus on respiratory infections. Drugs 62 (2002) 13-59